Engineered immune cells take on Hard-to-Treat gut cancers
NCT ID NCT06197178
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new treatment called LCAR-G08, which uses a patient's own immune cells (T-cells) that are modified in a lab to recognize and attack cancer cells in the gut. The study included 17 adults with advanced colorectal, stomach, pancreatic, or small bowel cancers that had a specific marker (GCC). The main goals were to check safety, find the right dose, and see if the treatment could shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTROINTESTINAL TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital & Institute
Beijing, Beijing Municipality, 100142, China
-
Beijing GoBroad Hospital
Beijing, Beijing Municipality, 102200, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Drug cocktail shrink stomach tumors before surgery?
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can High-Dose vitamin c boost Chemo's punch against pancreatic cancer?
- Can 3D motion capture reveal hidden breathing problems after esophageal cancer surgery?
- Can a simpler chemo schedule tame colorectal cancer with fewer side effects?